{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:49:04Z","timestamp":1778323744417,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"CZ innovation fund","award":["201600033"],"award-info":[{"award-number":["201600033"]}]},{"name":"MENZIS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13063-017-2134-x","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T11:12:39Z","timestamp":1504091559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Alfons A.","family":"den Broeder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise M.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogier","family":"Thurlings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart J. F.","family":"van den Bemt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Teerenstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Boers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank H. J.","family":"van den Hoogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,30]]},"reference":[{"key":"2134_CR1","first-page":"CD007356","volume":"1","author":"MA Lopez-Olivo","year":"2015","unstructured":"Lopez-Olivo MA, Amezaga UM, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015;1:CD007356.","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"2134_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15140","volume":"15","author":"K Malottki","year":"2011","unstructured":"Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15(14):1\u2013278.","journal-title":"Health Technol Assess"},{"issue":"9","key":"2134_CR3","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF Vollenhoven van","year":"2013","unstructured":"van Vollenhoven RF, Emery P, Bingham III CO, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496\u2013502.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2134_CR4","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF Vollenhoven van","year":"2015","unstructured":"van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11\u00a0years. J Rheumatol. 2015;42(10):1761\u20136.","journal-title":"J Rheumatol"},{"issue":"1","key":"2134_CR5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00003495-199958010-00009","volume":"58","author":"SV Onrust","year":"1999","unstructured":"Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs. 1999;58(1):79\u201388.","journal-title":"Drugs"},{"issue":"2","key":"2134_CR6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","volume":"40","author":"JC Edwards","year":"2001","unstructured":"Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40(2):205\u201311.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2134_CR7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","volume":"61","author":"MJ Leandro","year":"2002","unstructured":"Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61(10):883\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"2134_CR8","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572\u201381.","journal-title":"N Engl J Med"},{"issue":"2","key":"2134_CR9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/acr.22116","volume":"66","author":"M Bredemeier","year":"2014","unstructured":"Bredemeier M, de Oliveira FK, Rocha CM. Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(2):228\u201335.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"2134_CR10","first-page":"306","volume":"61","author":"V Bruzzese","year":"2009","unstructured":"Bruzzese V, Pepe J. Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab). Reumatismo. 2009;61(4):306\u20138.","journal-title":"Reumatismo"},{"issue":"1","key":"2134_CR11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/039463201102400135","volume":"24","author":"V Bruzzese","year":"2011","unstructured":"Bruzzese V. Therapeutic effectiveness of minimal doses of rituximab in a patient with rheumatoid arthritis. Int J Immunopathol Pharmacol. 2011;24(1):265\u20137.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"6","key":"2134_CR12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/1756-185X.12200","volume":"16","author":"V Bruzzese","year":"2013","unstructured":"Bruzzese V, Marrese C, Hassan C, Andriani A, Zullo A. Prompt efficacy of very low-dose rituximab on monoclonal B lymphocytosis in a rheumatoid arthritis patient. Int J Rheum Dis. 2013;16(6):764\u20135.","journal-title":"Int J Rheum Dis"},{"key":"2134_CR13","doi-asserted-by":"crossref","unstructured":"Shenoy P, Bavaliya M. Efficacy of very low dose (100\u00a0mg) rituximab in active rheumatoid arthritis despite combination DMARD-single center, prospective, observational study [abstract]. 67[Arthritis Rheumatology]. 29-9-2015. http:\/\/www.ard.bmj.com\/content\/74\/suppl_2\/1054.1 .","DOI":"10.1136\/annrheumdis-2015-eular.1314"},{"issue":"9","key":"2134_CR14","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793\u2013806.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2134_CR15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/art.30152","volume":"63","author":"EM Vital","year":"2011","unstructured":"Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603\u20138.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2134_CR16","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, Kaine JL, Lowenstein MB, Del GJ, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58(9):2652\u201361.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2134_CR17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.reuma.2015.07.003","volume":"12","author":"N Mena-Vazquez","year":"2016","unstructured":"Mena-Vazquez N, Manrique-Arija S, Urena-Garnica I, Romero-Barco CM, Jimenez-Nunez FG, Coret V, et al. Efficiency of different doses of rituximab in rheumatoid arthritis. Reumatol Clin. 2016;12(3):139\u201345.","journal-title":"Reumatol Clin"},{"issue":"9990","key":"2134_CR18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258\u201365.","journal-title":"Lancet"},{"key":"2134_CR19","unstructured":"Rituximab (Rituxan and MabThera). 2016. http:\/\/www.rheumatology.org\/I-Am-A\/Patient-Caregiver\/Treatments\/Rituximab-Rituxan-MabThera . Accessed 22 Aug 2017."},{"issue":"3","key":"2134_CR20","doi-asserted-by":"crossref","first-page":"e0119683","DOI":"10.1371\/journal.pone.0119683","volume":"10","author":"JT Joensuu","year":"2015","unstructured":"Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordstrom D, Blom M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015;10(3):e0119683.","journal-title":"PLoS One"},{"issue":"7","key":"2134_CR21","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/art.20350","volume":"50","author":"PM Welsing","year":"2004","unstructured":"Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum. 2004;50(7):2082\u201393.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2134_CR22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard.2009.109041","volume":"69","author":"RM Thurlings","year":"2010","unstructured":"Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(2):409\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2134_CR23","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1136\/annrheumdis-2013-203403","volume":"73","author":"M Ndosi","year":"2014","unstructured":"Ndosi M, Lewis M, Hale C, Quinn H, Ryan S, Emery P, et al. The outcome and cost-effectiveness of nurse-led care in people with rheumatoid arthritis: a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(11):1975\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2134_CR24","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1136\/annrheumdis-2013-203684","volume":"73","author":"JE Pope","year":"2014","unstructured":"Pope JE, Haraoui B, Thorne JC, Vieira A, Poulin-Costello M, Keystone EC. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6\u00a0months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis. 2014;73(12):2144\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"10041","key":"2134_CR25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(16)00380-9","volume":"388","author":"D Porter","year":"2016","unstructured":"Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016;388(10041):239\u201347.","journal-title":"Lancet"},{"issue":"1","key":"2134_CR26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44\u20138.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2134_CR27","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","volume":"41","author":"AM Gestel van","year":"1998","unstructured":"van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41(10):1845\u201350.","journal-title":"Arthritis Rheum"},{"issue":"27","key":"2134_CR28","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1002\/sim.4053","volume":"29","author":"S Everson-Stewart","year":"2010","unstructured":"Everson-Stewart S, Emerson SS. Bio-creep in non-inferiority clinical trials. Stat Med. 2010;29(27):2769\u201380.","journal-title":"Stat Med"},{"issue":"12","key":"2134_CR29","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3899\/jrheum.120573","volume":"39","author":"EC Keystone","year":"2012","unstructured":"Keystone EC, Cohen SB, Emery P, Kremer JM, Dougados M, Loveless JE, et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol. 2012;39(12):2238\u201346.","journal-title":"J Rheumatol"},{"issue":"9","key":"2134_CR30","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2134_CR31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2134_CR32","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2013-204920","volume":"74","author":"R Fleischmann","year":"2015","unstructured":"Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, et al. How much does disease activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? Ann Rheum Dis. 2015;74(6):1132\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1\u20132","key":"2134_CR33","first-page":"55","volume":"43","author":"M Boers","year":"1993","unstructured":"Boers M. International consensus on which measures to use in rheumatoid arthritis clinical trials. Neth J Med. 1993;43(1\u20132):55\u20138.","journal-title":"Neth J Med"},{"issue":"3","key":"2134_CR34","first-page":"199","volume":"16","author":"The EuroQol Group","year":"2016","unstructured":"The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 2016;16(3):199\u2013208.","journal-title":"Health Policy"},{"key":"2134_CR35","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2016. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40 . Accessed 22 Aug 2017."},{"issue":"20","key":"2134_CR36","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/sim.5352","volume":"31","author":"S Teerenstra","year":"2012","unstructured":"Teerenstra S, Eldridge S, Graff M, de Hoop E, Borm GF. A simple sample size formula for analysis of covariance in cluster randomized trials. Stat Med. 2012;31(20):2169\u201378.","journal-title":"Stat Med"},{"key":"2134_CR37","doi-asserted-by":"crossref","first-page":"h1389","DOI":"10.1136\/bmj.h1389","volume":"350","author":"N Herwaarden van","year":"2015","unstructured":"van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ. 2015;350:h1389.","journal-title":"BMJ"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-2134-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T23:09:43Z","timestamp":1570057783000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-2134-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,30]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2134"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-2134-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,30]]},"article-number":"403"}}